JUST IN: @US_FDA approved PARP inh Niraparib +abi/pred for BRCA2-mutated (BRCA2+) metastatic castration-sensitive prostate cancer (CSPC). Data based on AMPLITUDE trial showing rPFS benefit in the overall/BRCA population. Most benefit came from the BRCA2+ tumors: HR 0.46 (vs

Really excited to have our story on a CYP17A1-independent androgen biosynthesis pathway out today! We think this could be a reason for why androgens are left with abiraterone tx in prostate cancer. @dsui_miami_uro @SylvesterCancer @PCFnews @ASCO @AACR https://t.co/RqVWNMBnf2

Congrats to @kgre23 @BCM_InternalMed on matching for Heme/Onc fellowship to @utswcancer! Can’t wait to see what he’ll accomplish with mentorship from @TiansterZhang @HHammersMD @QianJanieQin and the outstanding GUMO group there.

Congrats on a brilliant match @nsayeghmd — the @MDAndersonNews fellowship is lucky to have matched you! Good to keep you in state as we have ongoing collaborations within the UT system. @DocMattCampbell @OAlhalabiMD @OncHahn

(4/4) OS analysis is immature, inconclusive with median fu of 20 months. Plan to update in ~ 1 year. Thank you to the patients, families, and providers who participated in this study.

(3/4) Len + eve had numerically higher SAEs, G3/4 AEs, and tx d/c than cabo, none significantly different between groups. 5/8 stopped len + eve for proteinuria

(2/4) Lenvatinib + everolimus significantly reduced the hazard for PD by 49% compared to cabozantinib. Len + eve also produced an ORR of 53% compared to 39% with cabo, not statistically significant.

(1/4) Here’s a tweetorial for LenCabo now available in @Annals_Oncology, https://t.co/qDJrPsv9yD This was a multicenter, phase 2 trial that randomized 90 patients with mccRCC and is the 1st head-to-head comparison of contemporary angiogenesis TT after PD-1 CPI

Beyond thrilled to have matched @MDAndersonNews for Hematology/Oncology fellowship!!! Immensely grateful to my mentor @neerajaiims, @Huntsman_GU, and all the incredible mentors who made this possible: @umangtalking @TiansterZhang @littlejonesmd @HHammersMD @OncHahn #Match2025

2/5 Clinically, 10 pts with RMC were treated; there were no confirmed responses, median PFS was ~1.4 months, and 5/10 met radiologic criteria for hyperprogression. Thus, for RMC immune checkpoint combination was not just ineffective; it could be harmful.

1/5 Our new @NatureComms study reports the first-ever dedicated clinical trial for #RenalMedullaryCarcinoma (RMC): phase II trial of #nivolumab + #ipilimumab and what it taught us about hyperprogression to immunotherapy: https://t.co/q1UwZr8L3i #endRMC #MsaouelLab @MDAndersonNews

An honor to take part in the DAVA GU Summit in Bermuda. Great start to the meeting. Proud of @CYJiangMD who presented her work on targeting TGF-B signaling in MTAP loss bladder cancer under mentorship of JJ Gao and @OAlhalabiMD sponsored by @ConquerCancerFd

This is great news for our patients, HLD-0915 and the AR RIPTAC tech will continue development with a strong team @BGarmezy @AarmstrongDuke @charlesryanmd @DCockrellMD

Incredible representation for chRCC at #IKCSNA25 including a phenomenal oral abstract presented by Sahil D. Doshi, MD summarizing the largest multi-institutional analysis to date on outcomes of metastatic chromophobe RCC with and without sarcomatoid features!

This is the most effective therapy we have developed to date for #RenalMedullaryCarcinoma contributing greatly to the recent doubling of median survival for this disease. Still much work to be done to #EndRMC and all rare &common #kidneycancer subtypes but the momentum is strong!

Terrific job by @sola_sesola2003 & team @NatRevUrol 👉PSMA-targeting therapies in #prostatecancer 👉molecular imaging & radionuclide Rx reshaping management strategies for advanced disease👉 https://t.co/jqYx3l6eIE Teaser👇@OncoAlert @urotoday @PCF_Science @DrMHofman #GaryCook

Great session at @KidneyCancer meeting on subsequent line therapy moderated by @AlbigesL and @WesleyYipMD with @MdArpita Lisa Henske, Martin Voss, and Anand Swamimath. Specially great discussion about radiation for oligoprogression! But I may be biased 😜

Congratulations to our incredible KCA Mentorship Academy mentees — and to Dr. Nizar Tannir, recipient of the 2025 KCA Mentorship Excellence Award! 🎉 #IKCSNA25

In a couple of minutes at #IKCSNA25, excited to talk about building a clinical trials program. Not sure that I have it right, but these are a couple of slides reflecting my personal thoughts below - hoping it will stimulate some good discussion! Thanks to @ZakhariaYousef

Strong data in metastatic ccRCC after prior PD-1 therapy 📊 • Lenvatinib + Everolimus vs Cabozantinib • PFS 15.7 vs 10.2 months (HR 0.51, p=0.02) • ORR 52.6% vs 38.6% • 1-year OS ~87% vs ~84.6% (immature) • Discontinuation for toxicity 20% vs 10.9% These results help guide